beatandraise

beta

Latest Financials

Filings:

By Category By Date Search Filings Institutional Holdersbeta Earnings Transcriptsbeta Global Search

Company Exhibits:

Indentures Material Contracts & Credit Agreements Plans of Reorganization Articles and Bylaws Underwriting Agreements

SEC Edgar

Annovis Bio, Inc.

SIC 2834 · Pharmaceutical Preparations

$ANVS

Annovis Bio, Inc.

CIK:0001477845|SEC Filings

Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
Statements of Operations - USD ($)	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses:
Research and development	$ 12,007,300	$ 5,161,921	$ 28,727,663	$ 10,173,438
General and administrative	2,370,412	1,109,532	3,662,232	2,380,696
Total operating expenses	14,377,712	6,271,453	32,389,895	12,554,134
Operating loss	(14,377,712)	(6,271,453)	(32,389,895)	(12,554,134)
Other income (expense):
Interest income	160,233	191,395	298,033	379,007
Other financing costs	(1,589,336)		(1,589,336)
Change in fair value of warrants	986,000	(140,000)	1,254,000	418,000
Total other income (expense), net	(443,103)	51,395	(37,303)	797,007
Net loss	$ (14,820,815)	$ (6,220,058)	$ (32,427,198)	$ (11,757,127)
Net loss per share
Basic (dollars per share)	$ (0.4)	$ (0.32)	$ (0.99)	$ (0.64)
Diluted (dollars per share)	$ (0.4)	$ (0.32)	$ (0.99)	$ (0.64)
Weighted-average number of common shares used in computing net loss per share
Basic	37,518,778	19,486,231	32,710,046	18,464,877
Diluted	37,518,778	19,486,231	32,710,046	18,464,877

Statements of Cash Flows - USD ($)	6 Months Ended
Statements of Cash Flows - USD ($)	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (32,427,198)	$ (11,757,127)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,791,478	996,505
Change in fair value of warrants	(1,254,000)	(418,000)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,758,859)	(950,568)
Accounts payable	736,622	(1,331,663)
Accrued expenses	1,986,713	255,800
Net cash used in operating activities	(30,925,244)	(13,205,053)
Cash flows from financing activities:
Proceeds from issuance of common stock, and warrants, net	30,105,566	19,783,423
Proceeds from exercise of common stock options	16,285
Net cash provided by financing activities	30,121,851	19,783,423
Net (decrease) increase in cash and cash equivalents	(803,393)	6,578,370
Cash and cash equivalents, beginning of period	19,532,338	10,551,916
Cash and cash equivalents, end of period	$ 18,728,945	$ 17,130,286

Balance Sheets - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 18,728,945	$ 19,532,338
Prepaid expenses and other current assets	3,308,146	1,549,287
Total assets	22,037,091	21,081,625
Current liabilities:
Accounts payable	3,327,138	2,590,516
Accrued expenses	3,031,571	1,044,859
Total current liabilities	6,358,709	3,635,375
Non-current liabilities:
Warrant liability	19,933,000	595,000
Total liabilities	26,291,709	4,230,375
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding
Common stock - $0.0001 par value, 70,000,000 shares authorized, 42,606,152 and 27,199,139 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	4,260	2,719
Additional paid-in capital	191,871,978	180,552,190
Accumulated deficit	(196,130,856)	(163,703,659)
Total stockholders' equity	(4,254,618)	16,851,250
Total liabilities and stockholders' equity	$ 22,037,091	$ 21,081,625